Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Eyenovia, Inc.
  6. News
  7. Summary
    EYEN   US30234E1047

EYENOVIA, INC.

(EYEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

EYENOVIA, INC. : Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits (form 8-K)

08/11/2021 | 04:16pm EDT

Item 2.02 Results of Operations and Financial Condition

On August 11, 2021, Eyenovia, Inc. issued a press release announcing its financial results for the fiscal second quarter and six months ended June 30, 2021. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference.

The information contained in, or incorporated into, Item 2.02, including the press release attached as Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference to such filing.



 Item 8.01. Other Events.




Attached hereto as Exhibit 99.2 and incorporated herein by reference is a corporate update presentation Eyenovia, Inc. intends to use with various investors and analysts.

Item 9.01. Financial Statements and Exhibits.




(d)   Exhibits



  Exhibit No.   Description

    99.1          Eyenovia, Inc. Press Release dated August 11, 2021

    99.2          Eyenovia, Inc. corporate update presentation dated August 2021

© Edgar Online, source Glimpses

All news about EYENOVIA, INC.
09/17EYENOVIA : Arctic Vision Expand Licence Deal to Include Another Eye Drug
MT
09/17Arctic Vision Announces Addition of Novel Mydriatic Drug Mydcombi™ to Eyenovia Commerci..
CI
09/15EYENOVIA : Material Definitive Agreement (Form 8-K)
PU
09/15EYENOVIA, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
09/15Eyenovia, Inc. Enters into Amendment to Certain License Agreement with Arctic Vision (H..
CI
08/12EYENOVIA : Management's Discussion and Analysis of Financial Condition and Results of Oper..
AQ
08/11EYENOVIA : Announced positive topline data from its Phase 3 VISION-1 study evaluating Micr..
PU
08/11EYENOVIA, INC. : Results of Operations and Financial Condition, Other Events, Financial St..
AQ
08/11Eyenovia, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
08/11Eyenovia Reports Second Quarter 2021 Financial Results
GL
More news
Analyst Recommendations on EYENOVIA, INC.
More recommendations
Financials (USD)
Sales 2021 3,49 M - -
Net income 2021 -22,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 -8,19x
Yield 2021 -
Capitalization 171 M 171 M -
Capi. / Sales 2021 48,9x
Capi. / Sales 2022 17,0x
Nbr of Employees 33
Free-Float 63,8%
Chart EYENOVIA, INC.
Duration : Period :
Eyenovia, Inc. Technical Analysis Chart | EYEN | US30234E1047 | MarketScreener
Technical analysis trends EYENOVIA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 6,58 $
Average target price 15,67 $
Spread / Average Target 138%
EPS Revisions
Managers and Directors
Sean Ianchulev President, CEO, Director & Chief Medical Officer
John P. Gandolfo Chief Financial Officer & Secretary
Fredric N. Eshelman Chairman
Luke Clauson VP-Engineering, Research & Development
Jennifer Clasby VP-Clinical Operations & Regulatory Affairs
Sector and Competitors
1st jan.Capi. (M$)
EYENOVIA, INC.8.58%171
JOHNSON & JOHNSON4.03%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.16.44%241 985
ELI LILLY AND COMPANY44.37%220 979